Ho Carole — SEC Form 4 filings
SEC reporting owner CIK 1724605. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-08.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-09 to 2026-06-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 7 filings — 62,529 shares, $1,319,068 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 14,098 shares @ $24.41 ($344,132) in Denali Therapeutics Inc., filed 2024-08-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | 10 | — | 12 legs · 62,529 sh · $1,319,068 | 6 |
| NGM BIOPHARMACEUTICALS INC (NGM) | Director | 1 | — | — | 4 |
| Royalty Pharma plc (RPRX) | Director | 2 | — | — | 3 |
| Beam Therapeutics Inc. (BEAM) | Director | 2 | — | — | 2 |
Form 4 filings — Ho Carole
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2025-08-14 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 2,937 @ $13.58 · Sale (S): 806 @ $14.64 | EDGAR |
| 2025-08-07 | 4 | Denali Therapeutics Inc. (DNLI) | Option exercise (M): 44,655 @ $0.68 · Option exercise (M): 44,655 (derivative) @ $0 | EDGAR |
| 2025-07-31 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 2,752 @ $0 · Grant/award (A): 5,806 @ $0 | EDGAR |
| 2025-06-06 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 12,255 @ $20.22 · Sale (S): 2,907 @ $20.81 | EDGAR |
| 2025-01-07 | 4 | Denali Therapeutics Inc. (DNLI) | Grant/award (A): 54,180 @ $0 · Grant/award (A): 162,540 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | Denali Therapeutics Inc. (DNLI) | Option exercise (M): 17,845 @ $0.68 · Option exercise (M): 17,845 (derivative) @ $0 | EDGAR |
| 2024-08-22 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 2,453 @ $23.79 · Sale (S): 14,098 @ $24.41 · Sale (S): 5,907 @ $24.96 | EDGAR |
| 2024-08-15 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 2,337 @ $22.89 | EDGAR |
| 2024-06-07 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 23,114 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | NGM BIOPHARMACEUTICALS INC (NGM) | Disposition to issuer (D): 78,407 (derivative) · Disposition to issuer (D): 24,222 (derivative) · Disposition to issuer (D): 19,619 (derivative) · Disposition to issuer (D): 39,515 (derivative) | EDGAR |
| 2024-02-15 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 2,784 @ $17.29 · Sale (S): 1,405 @ $17.79 | EDGAR |
| 2024-01-12 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 4,668 @ $19.02 | EDGAR |
| 2024-01-09 | 4 | Denali Therapeutics Inc. (DNLI) | Sale (S): 9,972 @ $19.43 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1724605 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →